RISK FACTOR AND PROGNOSIS OF RECURRENT IgA NEPHROPATHY AFTER KIDNEY TRANSPLANTATION

Yasuhiro Otsuka, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai, Asami Takeda Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital

INTRODUCTION AND AIMS

Study flow chart

There are a few studies showing that the long-term allograft survival of patients with IgA nephropathy (IgAN) is lower than that of non-IgAN, indicating that the cause of lower graft survival is recurrence of IgAN. There have been no large, prospective studies defining the risk factors contributing to the development of recurrent IgAN (rlgAN), and preventive therapy for rIgAN is unknown. The objective of this study is to assess prognosis for rIgAN and to find risk factors of rIgAN.

All RTx from 2002 to 2011: n=690 (LD 632, CD 58)	
piopsy-proven IgAN: n=69	
DM : n=7 NOT available for IF : n=0	


METHODS


Retrospective data were collected from 2002 to 2011 on 69 consecutive biopsy-proven IgAN patients who received kidney transplantation (KTx) at our center. 7 cases concurrent with diabetes mellitus were excluded. The cases of IgA vasculitis were not included in this study. The diagnosis of rlgAN was made by biopsy, and was defined as immunofluorescent positive staining for IgA in the mesangial area and active lesion in light microscopy including crescents and tuft necrosis with fibrin.

transmitted IgAN without disappearance of IgA deposition : n=0 non-adherence : n=0 cirrhosis, celiac disease : n=0 n=62 recurrent IgAN: n=4 non-recurrent IgAN: n=58

RESULTS									
	non-recurrent n=58	recurrent n=4	P-value	Immunosuppressive resimens	non-recurrent n=58	recurrent n=4	HLA mism	atch(es)	
Sex of the recipient M/F (cases)	34/24	3/1	0.642	PSL+CyA+MMF	29	3	5		
Recipient age at tx (years)	38.4±10.5	32.5±16.4	0.528	PSL+FK+MMF	9	0	ch(es)		
Donor age at tx (years)	55.6±9.2	56.8±3.3	0.528	PSL+GFK+MMF	5	0			
follow up (months)	65.8±34.1	76.0±37.1	0.627	PSL+CyA+EVR (without MMF)	2	0	A mis		_
max HbA1c (NGSP)	4.62±2.20	3.70±3.27	0.675	PSL+FK+MZ (without MMF)	2	0	H 1-		
Duration of dialysis (months)	35.7±56.3	7.8±14.2	0.0181	PSL+CyA+MZ (without MMF)	4	1	non-recurrent recurrent Mann-Whitney U test p=0.677		rent
Duration of CKD (months)(from RBx to ESRD)	115.1±75.0	73.8±109.3	0.507	PSL+CyA+CY	1	0			
PEKT (cases)	18	2	0.591	PSL+FK+CY	3	0			
HD (cases)	41	2	0.58	PSL+FK+CY+ALG	1	0			
PD (cases)	10	0	1	PSL+CyA+FTU720	1	0		non- recurrent	recurre
ABO incompatible (cases)	17	0	0.568		Fisher's exact test p=0.856		Rejection (+)	7	1
Pulse+Rit+PEx	6	2	0.0774				Rejection (-)	51	3
Steroid pulse	4	1	0.23					Fisher's exa	ct test p=0.4
Rituximab (cases)	3	2	0.0158						
DFPP and/or PEx (cases)	1	0	1						
Splenectomy (cases)	7	0	1	Doubling of serum creating	nine	Graft su			
MMF (cases)	44	3	1			1.0		+++++	
Basiliximab for induction (cases)	57	4	1	0.8 -		0.8 -	L		
living-related donor kidney (cases)	42	4	0.565	.6 −				L ₊₊	
tonsilx before tx (cases)	7	2	0.0971	9 2 4 0.4 -	L,	0.4 –			

	4.0212.20	0.10±0.21	0.070
Duration of dialysis (months)	35.7±56.3	7.8±14.2	0.0181
Duration of CKD (months)(from RBx to ESRD)	115.1±75.0	73.8±109.3	0.507
PEKT (cases)	18	2	0.591
HD (cases)	41	2	0.58
PD (cases)	10	0	1
ABO incompatible (cases)	17	0	0.568
Pulse+Rit+PEx	6	2	0.0774
Steroid pulse	4	1	0.23
Rituximab (cases)	3	2	0.0158
DFPP and/or PEx (cases)	1	0	1
Splenectomy (cases)	7	0	1
MMF (cases)	44	3	1
Basiliximab for induction (cases)	57	4	1
living-related donor kidney (cases)	42	4	0.565
tonsilx before tx (cases)	7	2	0.0971
tonsilx before tx + 1y after tx (cases)	19	2	0.599
donor-transmitted IgAN (cases)	5	1	0.357
IgA before tx (mg/dL)	246.1±94.2	347.5±85.6	0.329
HLA A2 (cases)	21	1	1





p=0.205

HLA B35 (cases)	3	1	0.251
HLA DR4 (cases)	35	1	0.289
HLA B8 (cases)	0	0	_
HLA DR3 (cases)	0	0	_

Duration of dialysis is significantly shorter in recurrent IgAN than in nonrecurrent IgAN (35.7 ± 56.3 months vs. 7.8 ± 14.2 months, p=0.0181). Duration from native kidney biopsy to end-stage renal disease in nonrecurrent IgAN and recurrent IgAN is 115.1 ± 75.0 months and 73.8 ± 109.3 months (p=0.507), respectively.

CONCLUSIONS

Short duration of dialysis was a risk factor for short time to doubling of serum creatinine in KTx in patients with recurrent IgAN.

References

1.Otsuka Y, Takeda A, Horike K, Inaguma D, Goto N, Watarai Y, Morozumi K: Early recurrence of active IgA nephropathy after kidney transplantation. Nephrology 19 Suppl 3: 45–48, 2014

2.Moroni G, Longhi S, Quaglini S, Gallelli B, Banfi G, Montagnino G, Messa P: The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrology Dialysis Transplantation 28: 1305–1314, 2013

